

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

Dinboeck, Michaela et al.

Examiner: Finn, Meghan R

INTERNATIONAL APPLICATION NO: PCT/EP2005/002809

FILED: March 16, 2005

U.S. APPLICATION NO: 10/592973

35 USC §371 DATE: November 07, 2006

FOR: USE OF RENIN INHIBITORS IN THERAPY

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☐ supplemental to the Information Disclosure Statement filed
- ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- ☐ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- ☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- ☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☐ The listed references were cited in the international stage search report. These references are of record in the instant PCT application PCT/EP2005/002809. Copies are being submitted.
- ☐ Copies of the non-asterisked references are enclosed herewith.
- ☐ Some of the non-asterisked references were cited in a search report in a corresponding application. Copies of these references and the search report are enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

- ☐ Certificate under 37 C.F.R. §1.97(e)(1): I, the undersigned Attorney, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ Statement under 37 C.F.R. §1.97(e)(2): I, the undersigned Attorney, hereby certify that no item of information in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-5442

Date: 19 AUG 2009

Respectfully submitted,



Lisa Matovcik
Attorney for Applicant
Reg. No. 53,283